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The evolution of resistance to a single antibiotic is frequently accompanied by increased resistance
to multiple other antimicrobial agents. In sharp contrast, very little is known about the frequency
and mechanisms underlying collateral sensitivity. In this case, genetic adaptation under antibiotic
stress yields enhanced sensitivity to other antibiotics. Using large-scale laboratory evolutionary
experiments with Escherichia coli, we demonstrate that collateral sensitivity occurs frequently
during the evolution of antibiotic resistance. Speciﬁcally, populations adapted to aminoglycosides
have an especially low ﬁtness in the presence of several other antibiotics. Whole-genome
sequencing of laboratory-evolved strains revealed multiple mechanisms underlying aminoglyco-
side resistance, including a reduction in the proton-motive force (PMF) across the inner membrane.
We propose that as a side effect, these mutations diminish the activity of PMF-dependent major
efﬂux pumps (including the AcrAB transporter), leading to hypersensitivity to several other
antibiotics. More generally, our work offers an insight into the mechanisms that drive the evolution
of negative trade-offs under antibiotic selection.
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Introduction
Evolutionary adaptation to an environment may be
accompanied by a decline or an increase in ﬁtness in other
environments. Although such trade-offs are frequently
observed in nature, the governing rules and the corresponding
molecular mechanisms are generally unclear. The evolution
of antibiotic resistance offers an ideal model system to
systematically investigate this issue. Enhanced level of
resistance can be achieved by mutations in the genome or by
acquisition of resistance-conferring genes through horizontal
gene transfer. The relative contribution of these mechanisms
depends both on the antibiotic employed and on the bacterial
species considered (Alekshun and Levy, 2007). It has been
suggested that the progressive accumulation of mutations can
simultaneously change an organism’s sensitivity to many
different antimicrobial agents and can serve as the ﬁrst step in
the evolution of clinically signiﬁcant resistance by more
speciﬁc and effective mechanisms (Baquero, 2001; Goldstein,
2007; Gullberg et al, 2011). A recent review argued that the
evolution of multidrug resistance and hypersensitivity are
among the central issues of the ﬁeld (Palmer and Kishony,
2013). Better understanding of these phenomena is important
as they could potentially inform future therapeutic strategies to
mitigate resistance evolution. For example, the choice of
optimal antibiotic combinations depends on both the presence
of physiological drug interactions and the frequency of
mutations with pleiotropic ﬁtness effects (Chait et al, 2007;
Palmer and Kishony, 2013; Pena-Miller et al, 2013).
Speciﬁcally, it remains unclear how frequently genetic
adaptation to a single antibiotic increases the sensitivity to
others and what the underlying molecular mechanisms of
hypersensitivity are. No large-scale, systematic laboratory
evolution study has been devoted to investigate this problem
under controlled environmental settings. To our best knowl-
edge, the only prior work with similar aims was published 60
years ago and was limited to phenomenological descriptions
(Szybalski and Bryson, 1952).
Here, for the ﬁrst time, we apply an integrated approach to
decipher collateral-sensitivity interactions between antibio-
tics.We initiated the laboratory evolution of E. coli populations
in the presence of one of the several different antimicrobial
agents. These antibiotics are well characterized, widely
employed in the clinic, and have diverse modes of actions
(Table I). Our list also includes antibiotics that are typically
used against Gram-positive bacteria. Consistent with previous
studies (Curtiss et al, 1965; Vuorio and Vaara, 1992; Elkins and
Nikaido, 2002), we found that these antibiotics inhibited
the growth of wild-type E. coli at high concentrations and
that resistance readily evolved against these compounds
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(see below). Next, we charted the network of collateral-
sensitivity interactions by measuring the susceptibility of each
evolved line against all the other antibiotics. Our analysis
revealed a strikingly dense network of collateral-sensitivity
interactions. Many of these interactions involved aminoglyco-
sides. Finally, laboratory-evolved lines were subjected to
whole-genome sequence analysis and biochemical assays to
decipher the underlying molecular mechanisms of these
interactions.
Results
Parallel evolution of antibiotic susceptibility
patterns in the laboratory
We followed established protocols withminormodiﬁcations to
evolve bacterial populations under controlled laboratory
conditions (Hegreness et al, 2008). Starting from a single
ancestral clone, populations were propagated in batch culture
(minimal glucose medium containing a single antibiotic),
whereby 1% of each culture was diluted into fresh medium on
a daily basis.
Microbes frequently encounter low or varying antibiotic
concentrations (Baquero, 2001). For example, the limited
accessibility of antibiotics to certain tissues or incomplete
treatment can lead to the formation of concentration gradients
within the body (Kohanski et al, 2010a). Similarly, antibiotic-
polluted natural environments generally form such gradients
radiating from the source. To mimic these natural conditions,
we employed two selection regimes. In the ﬁrst set of
experiments, a ﬁxed sublethal antibiotic concentration (i.e.,
sufﬁcient to reduce the growth of the starting population by
50%) was employed. Using this set-up, we propagated 10
independent populations in the presence of each antibiotic for
B140 generations, resulting in 240 parallel-evolved lines. As
selection pressure and resistance-conferring mutations can
differ substantially between low and high antibiotic concen-
trations, we also employed a complementary laboratory
evolutionary protocol. For an overlapping set of 12 selected
antibiotics (Table I), populations were allowed to evolve to
successively higher antibiotic concentrations (96 replicate
populations per antibiotic). Starting with subinhibitory anti-
biotic concentrations, the antibiotic concentration was
increased every 4 days over a period of 240–384 generations.
Despite the short evolutionary timescale, many of the evolved
populations reached very high resistance levels (20- to 328-
fold increases in the minimum inhibitory concentrations
(MICs); Supplementary Table S1). For each antibiotic, we
selected 10 independently evolved resistant populations for
further analysis (Materials and methods). In addition, to
control for potential adaptive changes that are not speciﬁc to
the employed antibiotics, we also established 10 parallel
populations that were grown in an environment devoid of
antibiotics, referred to as adapted control lines.
Next, we measured the corresponding changes in the
sensitivities of all laboratory-evolved populations to other
antibiotics. Fitness was measured by monitoring the optical
density of liquid cultures of all evolved and control lines in the
presence and absence of sublethal concentrations of anti-
biotics. Our protocol was highly sensitive and could efﬁciently
detect both weak negative and positive trade-offs, which may
be overlooked in other assays (Materials and methods;
Supplementary Text S1). Furthermore, by measuring ﬁtness
in antibiotic-free medium, we could distinguish between
general growth defects and genuine collateral-sensitivity
interactions. Speciﬁcally, we employed a rigorous statistical
procedure to identify those collateral-sensitivity interactions
that are not expected based on the generally weak growth
defect observed in the absence of antibiotics (see
Supplementary Text S2 and Supplementary Figure S3). The
reliability of the method was conﬁrmed by comparing its
results with sensitivity estimates based on the colony size
(Supplementary Text S2; Supplementary Figure S1).
We noticed that parallel-evolving populations exposed to
the same antibiotic displayed very similar antibiotic suscept-
ibility patterns (Supplementary Figure S2). Thus, we devel-
oped a data analysis pipeline to infer evolutionary interactions
at the level of antibiotic pairs based on the growth patterns of
the antibiotic-adapted and control populations. The analysis
ultimately led to a map of evolutionary interactions between
antibiotics (Figures 1A and B; Supplementary Table S2). In this
study, we concentrated on antibiotic pairs showing collateral
sensitivity; cross-resistance interactions will be described
elsewhere.
Table I Employed antibiotics and their modes of actions
Antibiotic name Abbreviation
Mode of
action
Bactericidal or
Bacteriostatic
Ampicillin AMP* Cell wall Bactericidal
Pipericallin PIP Cell wall Bactericidal
Cefoxitin FOX* Cell wall Bactericidal
Fosfomycin FOS Cell wall Bactericidal
Lomeﬂoxacin LOM Gyrase Bactericidal
Ciproﬂoxacin CPR* Gyrase Bactericidal
Nalidixic acid NAL* Gyrase Bactericidal
Fosmidomycin FSM Lipid Bactericidal
Nitrofurantoin NIT* Multiple
mechanisms
Bactericidal
Amikacin AMK Aminoglycoside Bactericidal
Gentamicin GEN Aminoglycoside Bactericidal
Kanamycin KAN* Aminoglycoside Bactericidal
Tobramycin TOB* Aminoglycoside Bactericidal
Streptomycin STR Aminoglycoside Bactericidal
Tetracycline TET* Protein
synthesis, 30S
Bacteriostatic
Doxycycline DOX* Protein
synthesis, 30S
Bacteriostatic
Chloramphenicol CHL* Protein
synthesis, 50S
Bacteriostatic
Erythromycin ERY* Protein
synthesis, 50S
Bacteriostatic
Fusidic acid FUS Protein
synthesis, 50S
Bacteriostatic
Sulfamonomethoxine SLF Folic acid
biosynthesis
Bacteriostatic
Trimethoprim TRM* Folic acid
biosynthesis
Bacteriostatic
Muporicin MUP Gram positive NA
Cycloserine CYC Gram positive NA
Vancomycin VAN Gram positive NA
The functional classiﬁcation is based on previous studies (Girgis et al, 2009; Yeh
et al, 2006). For an overlapping set of 12 selected antibiotics (indicated by stars),
populations were allowed to evolve in the presence of successively increased
antibiotic concentrations.
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Uneven distribution of collateral sensitivity across
antibiotic classes
The maps based on the evolutionary experiments performed
with constant and gradually increasing antibiotic concentra-
tions were similar. In all, 85% of the interactions between
antibiotics overlapped (Po10 5, randomization test). Three
main patterns emerge from our map. First, these interactions
occurred frequently: at least 35% of all investigated antibiotic
pairs showed collateral sensitivity in at least one direction.
Second, the mode of antibiotic action has a strong inﬂuence on
the distribution of interactions. Collateral sensitivity never
occurred between antibiotic pairs that target the same cellular
subsystem (Fisher’s exact test, P¼ 0.013). Thanks to systema-
tic chemogenomic studies, the mode of antibiotic action can be
deﬁned and compared in a more quantitative manner.
Speciﬁcally, a previous study exposed a nearly complete
mutagenized E. coli library to several antibiotics and
determined the ﬁtness contribution of individual genes
(Girgis et al, 2009). Using this data set, we calculated the
sets of genes that inﬂuence susceptibility for each antibiotic
used in our study (chemogenomic proﬁle). Collateral sensi-
tivity was depleted between antibiotic pairs with substantial
overlap in their chemogenomic proﬁles (Figure 1C). Third,
most antibiotic classes displayed collateral sensitivity
with relatively few other classes (Figure 1D). There was one
major exception: 44% of the collateral-sensitivity interactions
involved aminoglycosides. Genetic adaptation to aminoglyco-
sides increased the sensitivity to many other classes of
antibiotics, including inhibitors of DNA synthesis, cell-wall
synthesis, and other classes of protein synthesis inhibitors.
The observed interactions generally represented 2- to 10-fold
decreases in the MICs (Figure 2; Supplementary Table S3),
a result that is consistent with an earlier report on
antibiotic hypersensitivity (Szybalski and Bryson, 1952). This
rate is also rather similar to the 2- to 8-fold increases in MIC
typically observed in different efﬂux pump mutants (Piddock,
2006).
Figure 1 Networks of collateral-sensitivity interactions. Collateral-sensitivity interaction networks inferred from the adaptation to (A) low antibiotic concentrations and
(B) increasing concentrations of antibiotics. Antibiotics are grouped according to their mode of action. An arrow from antibiotic A to antibiotic B indicates that adaptation to
A increased the sensitivity to B. Aminoglycosides dominate the collateral-sensitivity network, with numerous links to other classes of antibiotics (red arrows).
(C) Collateral-sensitivity antibiotic pairs show relatively low overlap in their chemogenomic proﬁles (N¼ 120, Mann–Whitney U-test Po10 5). Chemogenomic distance
was calculated as pairwise Jaccard distance between sets of genes that inﬂuence antibiotic susceptibility (Girgis et al, 2009). Error bars indicate 95% conﬁdence
intervals. (D) Collateral-sensitivity interaction degrees of antibiotic classes (i.e., average number of antibiotic classes against which a population evolves hypersensitivity
if exposed to the antibiotic class shown on the vertical axis. Degrees are weighted by the number of antibiotics representing each class).
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Multiple mechanisms underlying aminoglycoside
resistance
Three major mechanisms of aminoglycoside resistance have
been recognized: inactivation of the drugs by aminoglycoside
modifying enzymes, modiﬁcation of ribosome, and decreased
membrane permeability (partly through changes in a mem-
brane potential). To gain insight into the molecular mechan-
isms underlying aminoglycoside resistance and collateral
sensitivity in our laboratory-evolved strains, we selected 14
clones evolved in the presence of a single aminoglycoside
(kanamycin, tobramycin, or streptomycin) for whole-genome
resequencing. All of these clones exhibited hypersensitivity to
other classes of antibiotics (Supplementary Tables S2 and S3).
The genomes of these independently evolved clones were
resequenced using the Applied Biosystems SOLiD platform,
and the identiﬁed single-nucleotide polymorphisms (SNPs)
were conﬁrmed using capillary sequencing.
In total, we identiﬁed 100 mutations (SNPs and indels)
affecting 44 protein-coding genes. On average, we observed
eight mutations per clone in lines adapted to increasing
concentrations and two mutations in those adapted to a ﬁxed
sublethal concentration (Supplementary Table S4). Three lines
of evidence indicated that these substitutions were driven by
adaptive evolution. First, 89% of the mutations were in
protein-coding regions and were non-synonymous. Second,
convergent evolution was prevalent at multiple levels, as a
total of 6.7% of the mutations at the single nucleotide level
were shared by two or more clones (Supplementary Table S4).
Evolutionary convergencewas evenmore apparent at the level
of genes and functional units, as a total of 29.5%of the affected
44 genes were mutated repeatedly (Supplementary Tables S4
and S5). Third, comparison with the results of available
chemogenomic screens revealed that 36% of the mutated
genes inﬂuence aminoglycoside susceptibility when inacti-
vated (Supplementary Table S4, P¼ 0.013, Fisher’s exact test).
Aminoglycosides directly target the ribosome. Mistransla-
tion and the consequent misfolding of membrane proteins
have an important role in aminoglycoside-induced oxidative
stress and cell death (Kohanski et al, 2010b). Aminoglycosides
Figure 2 Dose–response curve of selected aminoglycoside-adapted lineages exhibiting collateral sensitivity. Error bars indicate 95% conﬁdence intervals.
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generally require respiration for uptake (Taber et al, 1987) and
enter the cell in a membrane potential-dependent manner.
This process relies on cytochromes and the maintenance of the
proton-motive force (PMF) through the quinone pool
(Kohanski et al, 2010b).
Pathway enrichment analyses (Carbon et al, 2009) revealed
the overrepresentation of several biological processes in the
set of accumulated mutations (Supplementary Table S6). In
agreement with our expectations, one major target of selection
was the translational machinery, including several ribosomal
proteins, elongation factors (fusA, rpsL), and tRNA synthe-
tases. Second, several genes involved in membrane transport,
phospholipid synthesis, and cell envelope homeostasis were
mutated. Remarkably, this list included an oligopeptide
transporter (OppF) with a key role in the recycling of cell-
wall peptides and the two-component stress-response sensor
CpxA (Kohanski et al, 2008; Supplementary Table S4). The
biosynthesis of polyamines (including putrescine and spermi-
dine) was also affected. These molecules reduce the intracel-
lular production of reactive oxygen species during
aminoglycoside stress (Tkachenko et al, 2012) and thereby
diminish the levels of protein and DNA damage (Kohanski
et al, 2010b). Third, we identiﬁed a broad class of genes
expected to inﬂuence the membrane electrochemical potential
(Supplementary Tables S4 and S5; Figure 2B). These genes are
involved in oxidative phosphorylation, proton-potassium
symport (trkH), oxygen-binding heme biosynthesis (hemA),
while others are members of the cytochrome terminal oxidase
complex (cyoB, cyoC). They also frequently affect the quinone
pool, which serve as electron carriers in the respiratory
electron transport chain (IspA and the Nuo protein complex).
This third class most likely has a central contribution to the
collateral-sensitivity patterns observed, not least because all
sequenced clones had at least one mutation in this subsystem
(Supplementary Table S4).
Evidence for antagonistic mutational effects on
membrane permeability
Why should membrane potential affecting mutations alter the
susceptibility to multiple different antibiotics? These genes are
expected to inﬂuence aminoglycoside-induced oxidative stress
and/or aminoglycoside uptake. Indeed, aminoglycosides
uniquely require the PMF for active cellular uptake (Taber
et al, 1987; Allison et al, 2011). In sharp contrast, the efﬂux of
many other antibiotics depends on PMF-dependent pumps
(Paulsen et al, 1996). On the basis of these observations, we
propose a model in which low-level aminoglycoside resistance
is achieved by altering themembrane potential across the inner
bacterial membrane (Figure 3). As a secondary consequence,
these mutations diminish the activity of PMF-dependent major
efﬂux pumps. Indeed, it has been previously shown that CCCP,
a chemical inhibitor of oxidative phosphorylation, decreases
the intracellular accumulation of aminoglycosides (Allison
et al, 2011), but most likely increases the intracellular
accumulation of several other antibiotics (Coldham et al, 2010).
Along with the observed mutations, biochemical assays
provided further support for this model. First, we investigated
changes in the membrane potential in aminoglycoside-
resistant strains. The membrane potential was monitored
using the carbocyanine dye diethyloxacarbocyanine (DiOC2)
(3) (Novo et al, 2000). In agreement with our expectations, the
membrane potential was reduced in aminoglycoside-adapted
populations (Figure 4A; Supplementary Figure S4;
Figure 3 A putative mechanism underlying collateral sensitivity. (A) The
theory. Altering the membrane potential across the inner bacterial membrane has
two opposing effects: it reduces the uptake of many aminoglycoside-related
antibiotics but simultaneously may lead to the reduced activity of PMF-dependent
efﬂux pumps. For more details, see the main text. (B) Mutations supporting the
theory. Whole-genome sequencing revealed that adaptation to aminoglycosides
frequently proceeds through mutations that most likely diminish the generation of
the PMF. Mutations are indicated by red, bolded protein names (TrkH, CyoB,
HemA, IspA). The observed mutations in TrkH most likely increase the proton
inﬂux, whereas the mutations in CyoB and HemA (resulting in the inhibition of
proton translocation and heme biosynthesis, respectively) interfere with the
proper functioning of the cytochrome terminal oxidase complex. Furthermore,
decreased IspA activity reduces the levels of membrane-bound quinones and
therefore the level of oxidative phosphorylation. Altogether, these mutations likely
reduce the PMF and thus aminoglycoside uptake. Simultaneously, the activity of
the PMF-dependent efﬂux system is expected to decrease, resulting in greater
sensitivity to antibiotics transported by these pumps. AG, aminoglycoside; OM,
outer membrane; IM, inner membrane; NUO, NADH-Ubiquinone-oxidoreduc-
tase; PMF, proton-motive force.
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Supplementary Table S5). Simultaneously, these populations
showed elevated intracellular levels of the ﬂuorescent probe
Hoechst 33342 (Figure 4B; Supplementary Figure S5), indicat-
ing either increased porin activity or diminished efﬂux pump
activity (Coldham et al, 2010). This result contrasts with the
results for populations adapted to other antibiotic classes, as
these populations frequently exhibited reduced intracellular
levels of Hoechst 33342 (Figure 4B; Supplementary Figure S5).
The most direct evidence for antagonistic mutational effects
comes from a gene involved in Kþ uptake (trkH). Mutations in
trkH were observed in 64% of the sequenced aminoglycoside-
adapted populations. The amino-acid residue affected by one
of the observed mutations (T350L) is close to the ion channel
and therefore was chosen for further analysis. This mutation
was inserted into wild-type E. coli, and the inserted mutation
conferred mild resistance to aminoglycosides and, simulta-
neously, increased the susceptibility to other classes of
antibiotics, as expected (Figure 5A). Consistent with a causal
role of the PMF in this negative trade-off, this mutation
resulted in a diminished membrane potential and enhanced
the accumulation of Hoechst dye (Figures 5B and C). In further
support of the involvement of the PMF, a related regulator of
Kþ uptake has been shown to control both the membrane
potential and the multidrug susceptibility (Castaneda-Garcia
et al, 2011).
There are further examples supporting the scenario. The list
of mutated genes entails four genes (cyoB, ispA, nuoF, and
nuoE) with the following remarkable combination of proper-
ties (Supplementary Table S4). First, functional connection to
electron transport can be established based on the literature
data, strongly suggesting that these genes inﬂuence PMF.
Second, 57% of the observed mutations in these genes
generate frame-shift or in frame stop-codons, and hence most
likely yield proteins with compromised or no activities. Third,
null mutations in these genes reduce the aminoglycoside
susceptibility but enhance the sensitivity to other antibiotics.
Collateral sensitivity is partly linked to the AcrAB
efﬂux system
Recent studies systematically investigated the substrate
speciﬁcities of all major drug transporters through deletion
and overexpression over a wide range of drugs (Nishino and
Yamaguchi, 2001; Girgis et al, 2009; Liu et al, 2010; Nichols
et al, 2011). Comparison of results of chemogenomic screens
and our study revealed that as high as 75% of the antibiotics
showing collateral sensitivity with aminoglycosides are also
substrates of the AcrAB efﬂux pump system. This system is
member of the resistance nodulation family, and a major
multidrug resistance mechanism in E. coli. Overexpression of
this system confers resistance to a wide range of drugs and
detergents, but not to aminoglycosides (Okusu et al, 1996;
Nishino and Yamaguchi, 2001; Alekshun and Levy, 2007).
A proton electrochemical potential gradient across cell
membranes is the driving force for drug efﬂux by this system.
On the basis of these facts, we suggest that the AcrAB efﬂux
system has a key role in the collateral-sensitivity patterns
observed. More speciﬁcally, activity of this system is assumed
to be impaired in aminoglycoside-resistant lines due to the
presence ofmutations diminishing themembrane potential. To
test this hypothesis, we examined drug resistance phenotypes
conferred by the AcrAB efﬂux system in the presence/absence
of mutations in trkH and cyoB. As shown above, mutations in
these genes were frequently observed in aminoglycoside-
resistant lines, and we could conﬁrm that the corresponding
strains have diminished the membrane potential (Figures 4
and 5). We took advantage of the availability of a multicopy
plasmid that encodes the AcrAB transporter genes of E. coli
with the corresponding native promoters. Following protocols
of a prior study (Nishino and Yamaguchi, 2001), the plasmid
was transformed into wild-type and aminoglycoside-resistant
mutants. We tested the corresponding changes in susceptibil-
ities to four representative antibiotics (all of which are known
Figure 4 Membrane permeability (Hoechst dye) and membrane potential changes in evolved lines. (A) Membrane potential changes in antibiotic-adapted populations.
Changes in the membrane potential were monitored using the carbocyanine dye DiOC2(3). The red/green ﬂuorescence values for a representative set of
aminoglycoside- and non-aminoglycoside-adapted populations were determined relative to the average of those of three wild-type controls. The membrane potential was
signiﬁcantly reduced in aminoglycoside-resistant populations (Wilcoxon rank-sum test P¼ 0.002). Boxplots present the median and ﬁrst and third quartiles, with whiskers
showing either the maximum (minimum) value or 1.5 times the interquartile range of the data. The data are based on 10 and 22 measurements for aminoglycoside- and
non-aminoglycoside-adapted populations, respectively. (B) Substantial differences in the accumulation of the ﬂuorescent probe Hoechst 33342 across populations
adapted to different classes of antibiotics (10 evolved populations each) relative to wild-type controls. Boxplots present the median and ﬁrst and third quartiles, with
whiskers showing either the maximum (minimum) value or 1.5 times the interquartile range of the data, whichever is smaller (higher). The above ﬁgures are based on the
results for lineages evolved in the presence of constant sublethal antibiotic concentrations. For further results, see Supplementary Figures S4 and S5.
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substrates of the AcrAB efﬂux pump). First, strains with
deﬁcient AcrAB efﬂux system were sensitive to all four
antibiotics, regardless of the presence of mutations affecting
the membrane electrochemical potential (Figure 6). Second,
the AcrAB overexpression plasmid conferred a signiﬁcant
resistance to all four antibiotics in genotypes with wild-type
membrane potential. Third, and most strikingly, the same
plasmid conferred substantially weaker resistance when
introduced into the mutant lines (Figure 6). Taken together,
these results conﬁrm that mutations conferring aminoglyco-
side resistance via diminishing the membrane potential
increase the sensitivity to other agents by interfering with
the AcrAB efﬂux system.
Discussion
By combining experimental evolution, whole-genome sequen-
cing of laboratory-evolved bacteria and biochemical assays,
this work charted a map of collateral-sensitivity interactions
between antibiotics in E. coli, and aimed to understand these
negative evolutionary trade-offs. We demonstrated that
collateral-sensitivity interactions occurred at high rates.
Strikingly, laboratory evolution to different aminoglycoside
antibiotics frequently enhanced the sensitivity to many other
antimicrobial agents (2–10 fold MIC change). Whole-genome
sequencing of laboratory-evolved strains revealed multiple
mechanisms underlying aminoglycoside resistance. As
expected, the major targets of selection were the translational
machinery, membrane transport, phospholipid synthesis, and
cell envelope homeostasis. Strikingly, we also identiﬁed a
broad class of mutated genes involved in maintenance of the
membrane electrochemical potential. Notably, similar sets of
mutations have been observed in clinical and experimental
settings (Supplementary Table S4).
Aminoglycoside resistance can be achieved through reduc-
tion in the PMFacross the innermembrane (Proctor et al, 2006;
Pranting and Andersson, 2010). In this paper, we demonstrated
that these changes underlie the hypersensitivity of aminogly-
coside-resistant bacteria to several other antimicrobial agents,
Figure 5 Pleiotropic effects of a single mutation in trkH Individual antibiotic dose–response curves for growth inhibition were constructed for a trkH mutant strain. The
red line denotes the trkH mutant strain and the blue line indicates the corresponding wild-type control. Error bars indicate the standard errors based on four technical
replicates. A mutation in the trkH gene originally identiﬁed in a streptomycin-adapted population reduced the susceptibility to aminoglycosides but inhibited growth in the
presence of several non-aminoglycoside antibiotic stresses. For more details on minimum inhibitory changes, see Supplementary Table S7. This mutation also (B)
reduced the membrane potential (Wilcoxon rank-sum test P¼ 0.02, based on four replicate measurements) and (C) the enhanced accumulation of Hoechst dye
(Wilcoxon rank-sum test P¼ 0.0005, based on eight replicate measurements). Control populations treated with a chemical inhibitor of the PMF (CCCP) showed similar
patterns.
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partly through diminishing the activity of PMF-dependent
major efﬂux pumps. Taken together, these results indicate the
existence of an antagonistic mechanism by which bacteria
modulate intracellular antibiotic concentrations. Evolutionary
experiments performed with constant and gradually increas-
ing antibiotic concentrations yielded similar broad-scale
collateral-sensitivity patterns (see Figures 1A and B), and
one of the membrane potential affecting genes (trkH) was
repeatedly mutated in response to both treatments
(Supplementary Table S4). On the basis of these ﬁndings, we
speculate that the membrane potential affecting mutations
may arise at an early stage of resistance evolution.
Overexpression of a major multidrug transport (AcrAB)
conferred only a relatively low level of resistance in associa-
tion with PMF-affecting mutations. This result could have a
broad signiﬁcance. PMF-dependent efﬂux pumps are fre-
quently delivered by horizontal gene transfer, and have crucial
contribution to the evolution of multidrug resistance patterns
in a broad range of bacterial species (Paulsen et al, 1996;
Mine et al, 1999; Norman et al, 2008). Thus, resistance to one
antibiotic may not only confer changed sensitivity to another
antimicrobial agent, but also affect its further evolution (see
also Palmer and Kishony, 2013).
We emphasize that we do not consider our explanation
exclusive. However, we failed to ﬁnd evidence for other
mechanisms playing a role in the observed collateral-
sensitivity patterns of aminoglycoside-resistant populations.
Existing chemogenomic, literature, and experimental data are
fully consistent with our scenario (see Results). There is at
least one potentially interesting case that should be explored in
Figure 6 Link between the copy number of the major drug efﬂux system AcrAB and the extent of collateral-sensitivity interactions. The AcrAB efﬂux system confers
resistance to a variety of drugs, but not to aminoglycosides. Two aminoglycoside-resistant strains (trkH* and TOB3) and a wild-type strain (control) were modiﬁed either
by deleting the acrB gene (DacrB) or by harbouring a multicopy plasmid carrying the acrAB genes (pUCacrAB). Change of MIC in modiﬁed strains was measured using
E-test stripes containing one of four antibiotics (A) Chloramphenicol, (B) Ciproﬂoxacin, (C) Doxycycline, (D) Trimethoprim, representing different classes of modes of
action (Table I). The plasmid conferred a signiﬁcant resistance to all four antibiotics in control strain, but resistance levels were substantially reduced when the same
plasmid was associated with membrane potential affecting mutations in either trkH (trkH*) or both trkH and cyoB genes (TOB3).
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a future work. The elongation factor fusA was regularly
associated with aminoglycoside resistance in our experiments.
Previous works suggest that resistance conferred by fusA
mutations in Salmonella caused enhanced sensitivity to other
classes of antimicrobial agents (Macvanin and Hughes, 2005).
Strikingly, these mutations also caused low levels of heme
biosynthesis and reduced respiratory activity.
More generally, it will be important to determine how
conserved these networks of collateral-sensitivity interactions
are between bacterial species. Due to the similarities in the
cellular uptake mechanisms of aminoglycosides and cationic
antimicrobial peptides (Moore and Hancock, 1986), our results
may be more general. At least three mutated proteins (ArnC,
SbmA, and TrK) in our experiments inﬂuence resistance to
antimicrobial peptides (Supplementary Table S4), and more
generally, mutations in the heme biosynthesis pathway in
Salmonella provide resistance to several small peptides and
aminoglycosides and simultaneously increase the susceptibility
to other antibiotics (Pranting and Andersson, 2010).
Last, we need to emphasize the limitations of our work.
First, a substantial fraction of the collateral-sensitivity inter-
actions unrelated to aminoglycosides require mechanistic
explanation (Figure 1). Second, we neglected the evolution
of resistance through the acquisition of genes by horizontal
transfer. Third, due to the lack of systematic studies, the
frequency of PMF-altering mutations in clinical isolates is
largely unknown. Therefore, discussing the direct therapeutic
implications of our collateral-sensitivity network is beyond the
scope of this paper. It remains controversial whether the
temporal rotation or simultaneous use of two antibiotics can
select against the development of resistance (Bonhoeffer et al,
1997; Chait et al, 2007). The success of such strategies may
depend on the choice of antibiotics, as treatment with a single
antibiotic followed by a switch to a cross-sensitive partner
may represent a viable strategy. More generally, our work
established the prevalence of antagonistic pleiotropy during
the evolution of antibiotic resistance.
Materials and methods
Laboratory evolutionary experiments
We followed established protocols with minor modiﬁcations to evolve
resistant bacteria by propagating them in batch cultures in the
presence of antibiotics (Orlen and Hughes, 2006; Hegreness et al,
2008). Populations of Escherichia coli K12 (BW25113) were grown in
autoclaved MS-minimal medium supplemented with 0.2% glucose
and 0.1% casamino acids. Antibiotic solutions were prepared from
powder stocks and ﬁlter sterilized before use and diluted in the growth
media. Fresh antibiotic stocks were used on a weekly basis. Parallel
cultures were propagated in 96-well microtiter plates, continuously
shaken at B320 r.p.m. (301C). Plates were covered with special
sandwich covers (Enzyscreen) to ensure an optimal oxygen exchange
rate and limit evaporation. Every 24h, bacterial cells were transferred
by inoculating B1–1.2ml of stationary phase culture to 100ml fresh
medium using a 96-pin replicator (VP407) to give a daily dilution of
B100 or about 6–7 doublings. The evolved and control strains were
preserved at  801C in 20% (v/v) glycerol solution.
Constant, sublethal antibiotic dosage
Using sublethal antibiotic concentrations (approximately half max-
imal inhibitory concentrations, IC50), we propagated 10 independent
populations in the presence of each of the 24 antibiotics for B140
generations (Table I), resulting in 240 parallel-evolved lines. In
addition, to control for potential adaptive changes that are not speciﬁc
to the employed antibiotics, we also established 10 parallel popula-
tions growing in an environment devoid of antibiotics for B140
generations, referred to as adapted control lines. As expected, these
lines showed no major changes in antibiotic susceptibility. Plates
contained 36 bacteria-free wells to monitor potential contamination
events: all remained uncontaminated during the entire course of the
experiment. On average, the employed antibiotic had a mere 7%
inhibitory effect on the growth of laboratory-adapted populations.
Gradually increasing antibiotic dosage
In this experimental setting, populations were allowed to evolve to
successively higher antibiotic concentrations. Starting with a subinhi-
bitory (IC50) antibiotic concentration, antibiotic dosage was increased
gradually (1.5 times the previous dosage) at every fourth transfer. The
optical density at 600nm (OD600) of each well was measured in a
Biotek Synergy plate reader before each transfer. As expected, during
the course of laboratory evolution, populations grew to different
densities, reﬂecting independent evolutionary trajectories. Population
extinction was deﬁned as the failure to obtain growth (OD600o0.05).
The experiments ended once only 10 populations had showed growth
or antibiotic concentration had reached its upper solubility limit.
As this laboratory evolutionary protocol frequently leads to
extinction of bacterial populations, 96 independent parallel popula-
tions were propagated in the presence of each antibiotic. Due to the
large number of replicate lineages required, we concentrated on 12
selected antibiotics out of the 24 listed in Table I. This set still covers
diverse modes of actions, but includes only 1–2 members of each
major antibiotic class.
Most surviving bacterial populations from the ﬁnal day of the
experiments reached a very high resistance level, comparable to that
found in clinical isolates (Supplementary Table S1). Depending on the
antibiotics employed (and the corresponding extinction dynamics of
parallel evolving populations), the experiments lasted for B240–384
generations (Supplementary Table S1). For each antibiotic, 10 popula-
tionswith the highest cell densitieswere selected for further analysis.We
also established 10 parallel populations growing in an environment
devoid of antibiotics for the same number of transfers, referred to as
adapted control lines. Subsequently, we determined the antibiotic
susceptibilities of these selected populations against all other antibiotics.
Systematic measurement of antibiotic
susceptibilities
Given two panels of laboratory-evolved strains, our next goal was to
detect changes in their sensitivities towards other antimicrobial
agents. To this end, we developed a high-throughput screening
and robust statistical analysis methodology to systematically detect
collateral-sensitivity interactions in E. coli.
Growth measurement
Bacterial growthwasmonitored bymeasuring optical density (OD600)
of the liquid cultures at a single time point. Preliminary experiments
showed that a single reading of optical density after 14 h of incubation
shows very strong linear correlation (R240.99)with the area under the
growth curve, a descriptor of overall inhibitory effect that covers the
entire growth period (Supplementary Figure S6). We used a robotic
liquid handling system (Hamilton Star Workstation) to improve
reproducibility and thereby allowing us to perform hundreds of
growth measurements in parallel on 384-well microtiter plates. Slight
variations in temperature or humidity within the plate during
incubation may lead to local trends of altered growth (within-plate
effects). To overcome any measurement bias caused by the inhomo-
geneous environment and to convert raw OD values into relative
ﬁtness values that are comparable across plates, we employed a
normalization procedure as described in Supplementary Text S1.
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Estimating collateral sensitivity
We tested the sensitivity of each evolved line against the entire set of
antibiotics by measuring the growth in liquid cultures of all antibiotic-
adapted lines and adapted control lines at sublethal doses of antibiotics
(i.e., at around half-maximal effective concentration) in four technical
replicates (i.e., strains were cultivated in quadruplicate on the same
384-well plate). In addition, we also measured the growth of evolved
lines in a medium devoid of antibiotics to discern condition-speciﬁc
ﬁtness defects from general costs of resistance.
Because growth media with half-maximal effective concentrations
of antibiotics are difﬁcult to prepare in a reproducible manner, we
conducted four independent experimental runs for each combination
of strains and antibiotic conditions. Next, to ﬁlter out unreliable
measurements and those where the antibiotic dosage was too high to
detect collateral-sensitivity interactions, we excluded cases where
(i) cross-contamination might have occurred on the plate during
susceptibility measurements (based on the growth in non-inoculated
wells), (ii) the control wells devoid of antibiotics showed large
variations (coefﬁcient of variation was above 20%), (iii) the applied
antibiotic dosage was too high which strongly inhibited the growth of
the adapted control populations (490% effective concentration). This
quality control procedure resulted in 2–3 replicates for each combina-
tion of strains and antibiotics.
To identify statistically signiﬁcant collateral-sensitivity interactions,
we compared normalized growth values of evolved lines with that of
adapted control lines under the same treatment condition. Speciﬁcally,
using growth data on evolved lines in each antibiotic condition, we
tested whether growth of the 10 evolved lines, as a group, showed at
least 10% difference from that of the 10 adapted control lines, as a
group, under the same treatment condition. Statistical signiﬁcancewas
assessed using a non-parametric bootstrap method (Efron and
Tibshirani, 1994) and growth of each line was represented by the
median value of the four technical replicates. The P-values resulting
from independent experimental runs were combined using Fisher’s
combined probability test (data can be found in ‘P_values1’ sheets of
Supplementary Tables S8 and S9). As a ﬁnal step, we set up a rigorous
statistical procedure to ensure that the collateral-sensitive interactions
detected above are not due to general ﬁtness costs of resistance (see
Supplementary Text S2, data can be found in ‘RF_values’ and
‘P_values2’ sheets of Supplementary Tables S8 and S9). This yielded
a matrix of evolutionary interactions between antibiotics
(Supplementary Table S2). For more details on the accuracy of high-
throughput interaction measurements and control for potential
confounding factors, see Supplementary Text S2.
Whole-genome resequencing
Fourteen independently evolved clones were subjected to next-
generation sequencing to identify mutations responsible for the
resistant phenotype. All of them showed hypersensitivity towards
other classes of antibiotics, and two of them had evolved to constant,
sublethal antibiotic dosage. Brieﬂy, genomic DNA (gDNA) was
extracted from selected E. coli isolates (SIGMA GenElute Bacterial
Genomic DNA kit, standard procedures), fragmented, and SOLiD
sequencing adaptors were ligated. Subsequently, sequencing beads
were prepared and sequenced on the SOLiD System. As a result,
millions of short reads (50 or 75 bp) were generated along with data
indicating the sequencing quality of each nucleotide. Finally, variants,
such as SNP or multi-nucleotide polymorphism (MNP), insertions and
deletions (InDels), were identiﬁed compared with the reference E. coli
genome using standard bioinformatics analysis.
Preparation of the libraries and sequencings were performed by
cycled ligation sequencing on a SOLiD 5500xl System (Life Technol-
ogies; LT) using reagents and protocols provided by LT. Brieﬂy, 3 mg of
puriﬁed bacterial gDNA was fragmented by the Covaris S2 System to
150–350bp. The fragmented DNAwas end-repaired and ligated to P1
(50-CCACTACGCCTCCGCTTTCCTCTCTATGGGCAGTCGGTGAT-30) and
P2 (50CTGCCCCGGGTTCCTCATTCTCTGTGTAAGAGGCTGCTGACGGC
CAAGGCG-30) adapters, which provide the primary sequences for both
ampliﬁcation and sequencing of the sample library fragments. The P2
adapter contains a 10-bp barcode sequence which provided the basis
for multiplex sequencing. The templates were clonally ampliﬁed by
emulsion PCR (ePCR) with P1 primer covalently attached to the bead
surface. Emulsions were broken with butanol, and ePCR beads
enriched for template-positive beads by hybridization with P2-coated
capture beads. Template-enriched beads were extended at the 30 end in
the presence of terminal transferase and 30 bead linker. Beads with
clonally ampliﬁed DNA were then deposited onto a SOLiD Flowchip
(Ondov et al, 2010). About 250 million beads with clonally ampliﬁed
DNAwere deposited onto one lane of the ﬂowchip. The slide was then
loaded onto a SOLiD 5500xl instrument and the 50-base sequences
were obtained according to the manufacturer’s protocol.
Further analysis of genome sequences
The obtained sequences were aligned to the E. coli str. K-12 substr.
MG1655chromosome (Accession NC_000913; Version NC_000913.2
GI: 49175990). Alignment was performed using Genomics Workbench
(Floratos et al, 2010) 4.9 and theOmixonGapped SOLiDAlignment 1.3.2
plugin, provided by CLC Bio and Omixon, respectively. A minimum
average coverage of 50-fold was accomplished for each strain. The
maximum gap and mismatch count within a single read was set to 2
with a minimum of 4 reads to call a potential variation before further
analysis. Selected putative variants (SNPs and indels) detected by
whole-genome resequencing were veriﬁed by PCR followed by Sanger
sequencing on a 3500 Series Genetic Analyzer (LT). The primers were
designed using Genomics Workbench and are available on request.
Hoechst dye (H33342 bisbenzimide) accumulation
assay
To estimate changes in cellular permeability, we implemented a
recently developed and scalable ﬂuorescence assay (Coldham et al,
2010). The method is based on accumulation of the ﬂuorescent probe
Hoechst (H) 33342 (bisbenzimide). All laboratory-evolved popula-
tions were cultured overnight in MS-minimal medium supplemented
with 0.2% glucose and 0.1% casamino acid. Optical densities of
evolved bacterial populations were adjusted to OD600¼ 0.3. In all,
180ml aliquots of bacterial cultures were transferred to 96-well
microtiter plates (8 technical replicates per evolved line). Plates were
incubated in a Synergy 2microplate reader at 301C, and 25mMHoechst
dye (SIGMA) was added to each well using an auto-injection device
(BioTek dispenser box). The OD and ﬂuorescence curves were
measured for 1 h with 75-s delays between readings. The ﬁrst 15 data
points were excluded from further analysis due to the high standard
deviation between replicates. Blank normalized OD values were
calibrated as described in Supplementary Text S1. Data curves were
smoothed and ﬂuorescence per OD ratio curves were calculated. Next,
areas under these ratio curves were determined. Finally, we calculated
changes inHoechst dye accumulations relative to the appropriatewild-
type controls derived from the same experiment.
Measurement of bacterial membrane potential
Two adapted strains per each antibiotic selection regime were selected
randomly, and were subjected to membrane potential measurement.
The BacLight BacterialMembrane Potential Kit (B34950, Invitrogen)
was used to assess changes in PMF in the evolved strains. Brieﬂy,
DiOC2 exhibits green ﬂuorescence in all bacterial cells, but the
ﬂuorescence shifts towards red emission in cells maintaining
high membrane potential. The ratio of red to green ﬂuorescence
provides a measure of membrane potential that is largely independent
of cell size.
Overnight bacterial cultures were diluted toB106 cells/ml in ﬁltered
buffer (PBS). Aliquots of 200 ml bacterial suspension were added to
96-well microtiter plates for staining treatments. The DiOC2 dye was
added to each sample in a 0.03-mM concentration (no antibiotic was
added to the medium). After 30min of incubation, samples were
diluted 10-fold, andwere analysed by a GUAVA EasyCyte 8HTCapillary
Flow Cytometer. The instrument settings were adjusted according to
the BacLight kit manual. In all, 15000 events were recorded and gated
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out by visual inspection using the forward versus side scatter before
data acquisition. The red/green ﬂuorescence values for a representa-
tive set of aminoglycoside and non-aminoglycoside evolved popula-
tions were calculated relative to the average of three control wild-type
populations.
MIC and dose–response curve measurements
MICswere determined using a standard linear broth dilution technique
(Wiegand et al, 2008). In order to maximize reproducibility and
accuracy, we used a robotic liquid handling system (Hamilton Star
Workstation) to prepare 12 linear dilution steps automatically in
96-well microtiter plates. Approximately 106 bacteria/ml were inocu-
lated into each well with a 96-pin replicator, and were propagated at
301C shaken at 300 r.p.m. (4 replicates per strain/antibiotic concentra-
tion). After 24 h of incubation, raw OD values were measured in a
Biotek Synergy 2 microplate reader. MIC was deﬁned by a cutoff OD
value (i.e., meanþ 2 standard deviations of OD values of bacteria-free
wells containing only growth medium).
Allele replacements
Allele replacement in trkHwas constructed by a suicide plasmid-based
method in amarkerless allele replacement, which can be distinguished
by sequencing of the given chromosomal region. For details on
primer sequences, see Feher et al (2008). Standard steps and plasmids
(pST76-A, pSTKST) of the procedure have been described (Feher et al,
2008). In brief, an B800-bp long targeting DNA fragment carrying
the desired point mutation in the middle was synthesized by PCR,
then cloned into a thermosensitive suicide plasmid. The plasmid
construct was then transformed into the cell, where it was able to
integrate into the chromosome via a single crossover between the
mutant allele and the corresponding chromosomal region. The desired
cointegrates were selected by the antibiotic resistance carried on
the plasmid at a non-permissive temperature for plasmid replication.
Next, the pSTKST helper plasmid was transformed, then induced
within the cells, resulting in the expression of the I-SceI meganuclease
enzyme, which cleaves the chromosome at the 18-bp recognition site
present on the integrated plasmid. The resulting chromosomal gap is
repaired by way of RecA-mediated intramolecular recombination
between the homologous segments in the vicinity of the broken ends.
AcrAB efﬂux system and collateral sensitivity
To investigate the drug resistance phenotype conferred by the AcrAB
efﬂux system, three different strains were modiﬁed either by deleting
the acrB gene or by transforming a multicopy plasmid carrying the
AcrAB efﬂux pump (pUCacrAB) into various strains. The three
selected strains were the following: (i) the ancestral BW25113 strain
(control), (ii) an aminoglycoside-evolved line carrying mutations
in the trkH and cyoB genes (TOB3, see Supplementary Table S4), and
(iii) the ancestral strain carrying a mutation in trkH (T350L; the
corresponding strain will be referred to as trkH*). The appropriate
acrB deletion strains (DacrB/control, DacrB/trkH*, DacrB/TOB3)
were constructed using standard protocols by P1 transduction (Baba
et al, 2006; Miller, 1972).
To increase the copy number of the efﬂux pump, the plasmid
pUCacrAB with the corresponding native promoters was transformed
into the appropriate strains (pUCacrAB/control, pUCacrAB/trkH*,
pUCacrAB/TOB3) following the protocols of a prior study (Nishino
and Yamaguchi, 2001). The pUCacrAB plasmid was constructed and
provided us by Kunihiko Nishino and Akihito Yamaguchi (Osaka
University, Osaka, Japan).
Changes in susceptibility towards four representative antimicrobial
agents (chloramphenicol, ciproﬂoxacin, trimethoprim, and doxycy-
cline) were tested applying E-test stripes (bioMerieux). E-test
inoculum preparation and plating, strip application, and subsequent
MIC determinations were carried out in accordance with the
manufacturer’s instructions. The applied antibiotics represent differ-
ent classes of mode of action; however, the AcrAB efﬂux system is
known to cause resistance towards all of them.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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